Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation

Bibliography

• Cazzola M, Bardaro F, Stirpe E. The role of indacaterol for chronic obstructive pulmonary disease (COPD). J Thorac Dis 2013(19 Suppl 1):20-9
   Google Scholar
• Lombardi D, Cuenoud B, Krämer SD. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties? Eur J Pharm Sci 2009;38:533-47
   PubMed Web of Science ®Google Scholar
• Baur F, Beattie D, Beer D, et al. The identification of indacaterol as an ultra long-acting inhaled beta2-adrenoceptor agonist. J Med Chem 2010;53:3675-84
   PubMed Web of Science ®Google Scholar
• Cazzola M, Testi R, Matera MG. Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet 2002;41:19-30
   PubMed Web of Science ®Google Scholar
• Novartis. Indacaterol (QAB149) in Chronic Obstructive Pulmonary Disease (NDA 22-383). Briefing Document prepared by Novartis Pharmaceuticals for the Pulmonary-Allergy Drugs Advisory Committee meeting March 8 2011. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM245639.pdf [Last accessed 25 August 2013]
   Google Scholar
• Center for Drug Evaluation and Research. Application number: 022383Orig1s000. Pharmacology review(s). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000PharmR.pdf [Last accessed 25 August 2013]
   Google Scholar
• European Medicines Agency. Assessment Report for Onbrez Breezhaler. Procedure No. EMEA/H/C/001114. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001114/WC500053735.pdf [Last accessed 27 August 2013]
   Google Scholar
• Center for Drug Evaluation and Research. Application number: 022383Orig1s000. Clinical pharmacology and biopharmaceutics review(s). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022383Orig1s000ClinPharmR.pdf [Last accessed 28 August 2013]
   Google Scholar
• Emotte C, Heudi O, Deglave F, et al. Validation of an on-line solid-phase extraction method coupled to liquid chromatography-tandem mass spectrometry detection for the determination of Indacaterol in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2012;895-896:1-9
   PubMed Web of Science ®Google Scholar
• Kagan M, Dain J, Peng L, Reynolds C. Metabolism and pharmacokinetics of indacaterol in humans. Drug Metab Dispos 2012;40:1712-22
   PubMed Web of Science ®Google Scholar
• Mueller S, Haeberlin B, Edge S. Comparison of performance characteristics for Foradil Aerolizer® and Foradil Concept1 (a new single dose dry powder inhaler) at different test flow rates. Respir Drug Deliv 2008;3:675-8
   Google Scholar
• Perry S, Woessner R, Kaiser G, et al. Pharmacokinetics of indacaterol after single and multiple inhaled doses. Am J Respir Crit Care Med 2010;181:A4420
   Google Scholar
• McKeage K. Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease. Drugs 2012;72:543-63
   PubMed Web of Science ®Google Scholar
• Lock R, Price D, Khindri S, et al. Efficient deposition and absorption of orally inhaled indacaterol in the lungs [abstract no P252]. European Respiratory Society Annual Congress; 24 – 28 September 2011; Amsterdam
   Google Scholar
• Aubier M, Duval X, Knight H, et al. Indacaterol, a novel once-daily beta2-agonist, is effective and well tolerated on multiple dosing in patients with mild-to-moderate COPD. Eur Respir J 2005;26(Suppl):287S
   Google Scholar
• Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison. Respir Med 2008;102:1033-44
   PubMed Web of Science ®Google Scholar
• Pascoe S, Reynolds C, Pleskow W, et al. Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD. Int J Clin Pharmacol Ther 2011;49:153-61
   PubMed Web of Science ®Google Scholar
• Magnussen H, Verkindre C, Jack D, et al. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respir Med 2010;104:1869-76
   PubMed Web of Science ®Google Scholar
• Hosoe M, Woessner R, Matsushima S, et al. Efficacy, safety and pharmacokinetics of indacaterol in Caucasian and Japanese patients with chronic obstructive pulmonary disease: a comparison of data from two randomized, placebo controlled studies. Clin Drug Invest 2011;31:247-55
   PubMed Web of Science ®Google Scholar
• Matsushima S, Matthews I, Woessner R, et al. Systemic pharmacokinetics of indacaterol, an inhaled once-daily long-acting beta2-agonist, in different ethnic populations. Int J Clin Pharmacol Ther 2012;50:545-56
   PubMed Web of Science ®Google Scholar
• Khindri S, Sabo R, Harris S, et al. Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study. BMC Pulm Med 2011;11:31
   PubMedGoogle Scholar
• Barnes PJ, Pocock SJ, Magnussen H, et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm Pharmacol Ther 2010;23:165-71
   PubMed Web of Science ®Google Scholar
• Perry S, Goldsmith P, Vaidyanathan S, et al. No significant clinical drug-drug interaction potential with indacaterol [abstract no P3985]. European Respiratory Society Annual Congress; 24 – 28 September 2011; Amsterdam
   Google Scholar
• Vaisman N, Koren G, Goldstein D, et al. Pharmacokinetics of inhaled salbutamol in patients with cystic fibrosis versus healthy young adults. J Pediatr 1987;111:914-17
   PubMed Web of Science ®Google Scholar
• Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003;38:843-53
   PubMed Web of Science ®Google Scholar
• Schmekel B, Borgstrom L, Wollmer P. Difference in pulmonary absorption of inhaled terbutaline in healthy smokers and nonsmokers. Thorax 1991;46:225-8
   PubMed Web of Science ®Google Scholar
• Hochhaus G, Schmidt E, Rominger KL, Möllmann H. Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration. Pharm Res 1992;9:291-7
   PubMed Web of Science ®Google Scholar
• Naline E, Trifilieff A, Fairhurst RA, et al. Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur Respir J 2007;29:575-81
   PubMed Web of Science ®Google Scholar
• Cazzola M, Segreti A, Stirpe E, et al. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol. Respir Med 2013;107:107-11
   PubMed Web of Science ®Google Scholar
• García-Martín E, Canto G, Agúndez JA. Metabolic considerations of drugs in the treatment of allergic diseases. Expert Opin Drug Metab Toxicol 2013;9:1437-52
   PubMed Web of Science ®Google Scholar
• Cazzola M, Proietto A, Matera MG. Indacaterol for chronic obstructive pulmonary disease (COPD). Drugs Today (Barc) 2010;46:139-50
   PubMed Web of Science ®Google Scholar
• Donohue JF, Singh D, Kornmann O, et al. Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis 2011;6:477-92
   PubMed Web of Science ®Google Scholar